Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$8.04 USD

8.04
56,533

+0.25 (3.25%)

Updated Sep 19, 2024 10:23 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Balance Sheet

Research for BAYRY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Bayer Aktiengesellschaft falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 11,627 10,935 9,354 13,857 6,172
Receivables 13,870 14,479 15,714 14,227 16,958
Notes Receivable 0 0 0 0 0
Inventories 15,095 14,367 13,386 12,521 12,062
Other Current Assets 55 3 90 129 1,273
Total Current Assets 40,647 39,784 38,543 40,734 36,466
Net Property & Equipment 14,417 14,407 15,011 13,376 13,976
Investments & Advances 3,374 3,100 3,141 2,337 2,305
Other Non-Current Assets 1,225 1,122 1,628 954 841
Deferred Charges 5,921 5,905 5,419 5,353 5,125
Intangibles 60,243 67,252 78,515 70,947 82,695
Deposits & Other Assets 0 0 0 0 0
Total Assets 125,827 131,570 142,257 133,702 141,409
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8,070 7,949 8,036 6,492 7,197
Current Portion Long-Term Debt 7,392 8,282 5,195 9,790 2,444
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 670 1,113 812 2,592 849
Other Current Liabilities 15,750 19,620 20,744 23,081 15,511
Total Current Liabilities 31,881 36,965 34,787 41,954 26,001
Mortgages 0 0 0 0 0
Deferred Taxes/Income 855 766 1,101 1,520 4,206
Convertible Debt 0 0 0 0 0
Long-Term Debt 41,318 35,602 43,161 37,920 41,341
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 15,973 17,225 23,967 17,240 16,642
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 90,027 90,558 103,016 98,634 88,190
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2,722 2,650 2,976 2,873 2,817
Capital Surplus 19,764 19,240 21,605 20,860 20,452
Retained Earnings 0 0 0 0 0
Other Equity 13,314 19,123 14,661 11,335 29,950
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 35,800 41,012 39,241 35,067 53,219
Total Liabilities & Shareholder's Equity 125,827 131,570 142,257 133,702 141,409
Total Common Equity 35,800 41,012 39,241 35,067 53,219
Shares Outstanding NA 3,929.70 3,929.70 3,929.70 3,730.20
Book Value Per Share -0.36 10.44 9.99 8.92 14.27

Fiscal Year End for Bayer Aktiengesellschaft falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 10,795 9,687 11,627 10,129 8,320
Receivables 18,341 19,319 13,870 15,514 18,935
Notes Receivable 0 0 0 0 0
Inventories 14,094 14,589 15,095 15,190 15,013
Other Current Assets 1 15 55 13 15
Total Current Assets 43,231 43,609 40,647 40,845 42,282
Net Property & Equipment 14,524 14,627 14,417 14,638 14,368
Investments & Advances 3,423 3,476 3,374 3,070 3,050
Other Non-Current Assets 1,348 1,301 1,225 1,273 1,322
Deferred Charges 6,371 6,228 5,921 5,691 5,827
Intangibles 60,178 60,914 60,243 62,088 65,817
Deposits & Other Assets 0 0 0 0 0
Total Assets 129,076 130,155 125,827 127,606 132,666
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 6,598 6,946 8,070 7,075 6,510
Current Portion Long-Term Debt 9,887 8,991 7,392 13,401 10,860
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 976 1,110 670 849 871
Other Current Liabilities 16,527 16,208 15,750 14,680 16,855
Total Current Liabilities 33,988 33,255 31,881 36,005 35,097
Mortgages 0 0 0 0 0
Deferred Taxes/Income 900 850 855 799 782
Convertible Debt 0 0 0 0 0
Long-Term Debt 40,273 41,242 41,318 38,215 39,862
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 15,311 15,973 16,075 16,445
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 90,473 91,328 90,027 91,094 92,186
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2,708 2,731 2,722 2,737 2,742
Capital Surplus 19,665 19,826 19,764 19,875 19,912
Retained Earnings 0 0 0 0 0
Other Equity 16,230 16,270 13,314 13,900 17,826
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 38,604 38,827 35,800 36,513 40,480
Total Liabilities & Shareholder's Equity 129,076 130,155 125,827 127,606 132,666
Total Common Equity 38,604 38,827 35,800 36,513 40,480
Shares Outstanding NA NA NA NA NA
Book Value Per Share -0.39 -0.39 -0.36 -0.37 -0.40